Literature DB >> 29699791

Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010-2015.

Sydel R Parikh1, Helen Campbell2, Stephen J Gray3, Kazim Beebeejaun2, Sonia Ribeiro2, Ray Borrow4, Mary E Ramsay2, Shamez N Ladhani5.   

Abstract

The epidemiology of invasive meningococcal disease (IMD) is constantly changing as new strains are introduced into a population and older strains are removed through vaccination, population immunity or natural trends. Consequently, the clinical disease associated with circulating strains may also change over time. In England, IMD incidence has declined from 1.8/100,000 in 2010/2011 to 1.1/100,000 in 2013/2014, with a small increase in 2014/2015 to 1.3/100,000. Between 01 January 2011 and 30 June 2015, MenB was responsible for 73.0% (n = 2489) of 3411 laboratory-confirmed IMD cases, followed by MenW (n = 371, 10.9%), MenY (n = 373, 10.9%) and MenC (n = 129, 3.8%); other capsular groups were rare (n = 49, 1.4%). Detailed questionnaires were completed for all 3411 laboratory-confirmed cases. Clinical presentation varied by capsular group and age. Atypical presentations were uncommon (244/3411; 7.2%), increasing from 1.2% (41/3411) in children to 3.5% (120/3411) in older adults. Known IMD risk factors were rare (18/3411; 0.5%) and included complement deficiency (n = 11), asplenia (n = 6) or both (n = 1). Nearly a third of cases required intensive care (1069/3411; 31.3%), with rates highest in adults. The 28-day CFR was 6.9% (n = 237), with the lowest rates in 0-14 year-olds (85/1885, 4.5%) and highest among 85+ year-olds (30/94, 31.9%). These observations provide a useful baseline for the current burden of IMD in a European country with enhanced national surveillance.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Case fatality; Epidemiology; Meningococcal disease; Risk factors; Surveillance

Mesh:

Year:  2018        PMID: 29699791     DOI: 10.1016/j.vaccine.2018.02.038

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

Review 1.  Epidemiology of invasive meningococcal disease in Greece, 2006-2016.

Authors:  Anastasia Flountzi; Theano Georgakopoulou; Sooria Balasegaram; Konstantinos Kesanopoulos; Athanasia Xirogianni; Anastasia Papandreou; Georgina Tzanakaki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-15       Impact factor: 3.267

2.  Invasive meningococcal disease in patients with complement deficiencies: a case series (2008-2017).

Authors:  Shamez N Ladhani; Helen Campbell; Jay Lucidarme; Steve Gray; Sydel Parikh; Laura Willerton; Stephen A Clark; Aiswarya Lekshmi; Andrew Walker; Sima Patel; Xilian Bai; Mary Ramsay; Ray Borrow
Journal:  BMC Infect Dis       Date:  2019-06-14       Impact factor: 3.090

3.  Transmissibility and pathogenicity of the emerging meningococcal serogroup W sequence type-11 complex South American strain: a mathematical modeling study.

Authors:  Matthieu Domenech de Cellès; Helen Campbell; Ray Borrow; Muhamed-Kheir Taha; Lulla Opatowski
Journal:  BMC Med       Date:  2020-04-22       Impact factor: 8.775

4.  Atypical presentation of invasive meningococcal disease caused by serogroup W meningococci.

Authors:  C Stinson; C Burman; J Presa; M Abalos
Journal:  Epidemiol Infect       Date:  2020-01-27       Impact factor: 2.451

Review 5.  A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines.

Authors:  Jamie Findlow; Paul Balmer; Ray Borrow
Journal:  Hum Vaccin Immunother       Date:  2019-04-23       Impact factor: 3.452

6.  A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model.

Authors:  Lorenzo Argante; Victoria Abbing-Karahagopian; Kumaran Vadivelu; Rino Rappuoli; Duccio Medini
Journal:  BMC Infect Dis       Date:  2021-12-11       Impact factor: 3.090

7.  Clinical and Laboratory Findings of 12 Children with Invasive Meningococcal Disease in Pediatric Intensive Care Unit.

Authors:  Eylem Kiral; Ayse Filiz Yetimakman
Journal:  Crit Care Res Pract       Date:  2021-09-04

8.  Evaluation of pharyngeal carriage of Neisseria meningitidis in Tehran, Iran.

Authors:  A Fahimzad; M Khatmi; F Shiva; S E Mortazavi; F Shirvani; F A Gorji
Journal:  New Microbes New Infect       Date:  2022-01-10

9.  Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database.

Authors:  Catherine Weil-Olivier; Muhamed-Kheir Taha; Stéphane Bouée; Corinne Emery; Véronique Loncle-Provot; Gaëlle Nachbaur; Ekkehard Beck; Céline Pribil
Journal:  Hum Vaccin Immunother       Date:  2022-02-22       Impact factor: 3.452

Review 10.  Human genetics of meningococcal infections.

Authors:  Stephanie Hodeib; Jethro A Herberg; Michael Levin; Vanessa Sancho-Shimizu
Journal:  Hum Genet       Date:  2020-02-17       Impact factor: 4.132

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.